Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 219pembrolizumab 199Magnetic Resonance Spectroscopy 197Carboplatin 173Cisplatin 139Biopsy 133Nivolumab 129Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 76Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Doxorubicin 65Bevacizumab 65Docetaxel 62Ipilimumab 58Etoposide 57olaparib 55Fluorouracil 52venetoclax 50Taxes 50Radiosurgery 50Oxaliplatin 50Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × guadecitabine × 90 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02998567 2026-05-12

HyPeR

Royal Marsden NHS Foundation Trust

Phase 1 Active not recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡